Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and...
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
Spectrum's Biologic Rolvedon (Eflapegrastim) Receives Approval in the U.S.
BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
Assertio Holdings has reached a definitive agreement to purchase all outstanding shares of Spectrum Pharmaceuticals in an all-stock and contingent value rights (CVR) deal.
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services